VA Awards $1.05M for Contrast Injectors to Bayer Healthcare, Sole Source
Contract Overview
Contract Amount: $105,243 ($105.2K)
Contractor: Bayer Healthcare LLC
Awarding Agency: Department of Veterans Affairs
Start Date: 2025-02-12
End Date: 2026-02-11
Contract Duration: 364 days
Daily Burn Rate: $289/day
Competition Type: NOT COMPETED
Number of Offers Received: 1
Pricing Type: FIRM FIXED PRICE
Sector: Healthcare
Official Description: CONTRAST INJECTORS
Place of Performance
Location: BALTIMORE, BALTIMORE CITY County, MARYLAND, 21201
State: Maryland Government Spending
Plain-Language Summary
Department of Veterans Affairs obligated $105,242.58 to BAYER HEALTHCARE LLC for work described as: CONTRAST INJECTORS Key points: 1. High value contract for essential medical equipment. 2. Sole source award limits competitive pricing. 3. Potential risk of overpayment due to lack of competition. 4. Focus on healthcare sector, specifically surgical instruments.
Value Assessment
Rating: questionable
Pricing is difficult to assess without competitive benchmarks. The sole-source nature suggests potential for higher costs than if multiple vendors were considered.
Cost Per Unit: N/A
Competition Analysis
Competition Level: sole-source
This contract was awarded sole-source, meaning only one vendor was considered. This significantly limits price discovery and competitive pressure, potentially leading to higher costs for the government.
Taxpayer Impact: Taxpayers may bear a higher cost due to the lack of competition in this sole-source award.
Public Impact
Ensures availability of critical medical devices for veterans. Potential for increased healthcare costs if pricing is not optimized. Highlights reliance on specific manufacturers for specialized equipment.
Waste & Efficiency Indicators
Waste Risk Score: 50 / 10
Warning Flags
- Sole-source award
- Lack of competitive bidding
- Potential for price inflation
Positive Signals
- Ensures supply of critical medical equipment
- Supports veteran healthcare services
Sector Analysis
This contract falls within the healthcare sector, specifically the manufacturing of surgical and medical instruments. Spending benchmarks for contrast injectors can vary widely based on technology and volume, but sole-source awards often deviate from optimal pricing.
Small Business Impact
No indication of small business participation in this sole-source award. The focus is on a large, established healthcare provider.
Oversight & Accountability
The sole-source justification needs thorough review to ensure it was appropriate and that the price negotiated is fair and reasonable given the lack of competition.
Related Government Programs
- Surgical and Medical Instrument Manufacturing
- Department of Veterans Affairs Contracting
- Department of Veterans Affairs Programs
Risk Flags
- Sole-source award lacks competition.
- Potential for inflated pricing.
- Limited transparency in price negotiation.
- Reliance on a single vendor.
Tags
surgical-and-medical-instrument-manufact, department-of-veterans-affairs, md, definitive-contract, 100k-plus
Frequently Asked Questions
What is this federal contract paying for?
Department of Veterans Affairs awarded $105,242.58 to BAYER HEALTHCARE LLC. CONTRAST INJECTORS
Who is the contractor on this award?
The obligated recipient is BAYER HEALTHCARE LLC.
Which agency awarded this contract?
Awarding agency: Department of Veterans Affairs (Department of Veterans Affairs).
What is the total obligated amount?
The obligated amount is $105,242.58.
What is the period of performance?
Start: 2025-02-12. End: 2026-02-11.
What is the justification for the sole-source award, and was a market research conducted to confirm no other viable sources exist?
The justification for a sole-source award typically involves specific circumstances, such as unique capabilities, urgent needs, or the unavailability of alternatives. A thorough market research report should have been conducted to validate that no other responsible sources could meet the government's requirements. Without this documentation, the sole-source determination is questionable.
How was the price determined to be fair and reasonable without competitive bids?
Determining price reasonableness for a sole-source contract often relies on historical pricing data, commercial price lists, or cost analysis techniques. The agency should have performed a detailed price analysis, potentially comparing the proposed price to similar items purchased previously or to prices charged to other customers. The absence of competition makes this analysis critical.
What is the long-term strategy for acquiring contrast injectors to ensure competitive pricing in the future?
The long-term strategy should involve exploring options to foster competition, such as breaking down the requirement into smaller lots, encouraging new market entrants, or re-evaluating the necessity of sole-source procurement for future needs. Proactive market research and engagement with potential vendors can help mitigate future sole-source awards.
Industry Classification
NAICS: Manufacturing › Medical Equipment and Supplies Manufacturing › Surgical and Medical Instrument Manufacturing
Product/Service Code: MEDICAL SERVICES › MEDICAL, DENTAL, AND SURGICAL SVCS
Competition & Pricing
Extent Competed: NOT COMPETED
Solicitation Procedures: ONLY ONE SOURCE
Offers Received: 1
Pricing Type: FIRM FIXED PRICE (J)
Evaluated Preference: NONE
Contractor Details
Address: 100 BAYER BLVD, WHIPPANY, NJ, 07981
Business Categories: Category Business, Corporate Entity Not Tax Exempt, Not Designated a Small Business, Special Designations, U.S.-Owned Business
Financial Breakdown
Contract Ceiling: $150,375
Exercised Options: $105,243
Current Obligation: $105,243
Contract Characteristics
Commercial Item: COMMERCIAL PRODUCTS/SERVICES
Cost or Pricing Data: NO
Timeline
Start Date: 2025-02-12
Current End Date: 2026-02-11
Potential End Date: 2028-02-12 00:00:00
Last Modified: 2026-04-10
More Contracts from Bayer Healthcare LLC
Other Department of Veterans Affairs Contracts
- CCN Region 3 Express Report — $5.2B (Optum Public Sector Solutions, Inc.)
- Express Report for FY22 Region 2 — $5.1B (Optum Public Sector Solutions, Inc.)
- Fiscal Year 2022 Express Report for Region 1 — $4.2B (Optum Public Sector Solutions, Inc.)
- Express Report for the Patient Centered Community Care (PC3) Contract — $3.3B (Triwest Healthcare Alliance Corp)
- CCN Region Three FY21 Express Report — $3.1B (Optum Public Sector Solutions, Inc.)